Drug intelligence / Profile preview

426c.Mod.Core-C4b

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

426c.Mod.Core-C4b is an experimental HIV vaccine candidate designed as a self-assembling nanoparticle immunogen targeting the CD4 binding site (CD4bs) of the HIV-1 envelope. It is specifically engineered to elicit VRC01-class broadly neutralizing antibody (bnAb) precursor B-cell lineages, which are known for their high potency and breadth against diverse HIV strains. The immunogen consists of core inner and outer domains from the Clade C 426c transmitted founder viral envelope, with modifications such as removal of V1-V3 loops and certain glycans around the CD4bs to enhance germline binding, including retention of N276 glycan. The vaccine is adjuvanted with 3M-052-AF (a TLR7/8 agonist) plus aluminum hydroxide (Alum), aiming to boost immune responses. It is being evaluated in phase 1 clinical trials for safety and immunogenicity in both people living with HIV undergoing analytical treatment interruption and in infants perinatally exposed to HIV but uninfected[1][2][5][6][7].

Brand names: 426c.Mod.Core-C4b
Other names: 426c.Mod.Core-C4b vaccine

Targets

TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on 426c.Mod.Core-C4b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 426c.Mod.Core-C4b.

Explore the full profile